Q3 EPS Estimate for Oruka Therapeutics Decreased by Analyst

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for Oruka Therapeutics in a note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of ($0.60) for the quarter, down from their prior estimate of ($0.33). The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($1.76) EPS, FY2028 earnings at ($1.93) EPS and FY2029 earnings at ($1.59) EPS.

ORKA has been the subject of a number of other research reports. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday. BTIG Research assumed coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a “buy” rating for the company. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Buy” and an average price target of $40.38.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $15.37 on Thursday. The company has a market cap of $575.61 million, a PE ratio of -5.47 and a beta of -0.35. The company has a fifty day moving average price of $13.35 and a two-hundred day moving average price of $11.53. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $52.32.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ORKA. Legal & General Group Plc acquired a new position in shares of Oruka Therapeutics during the second quarter valued at $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics during the second quarter valued at $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at $54,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Oruka Therapeutics during the second quarter valued at $68,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.